Theralase Technologies Inc. V.TLT

Polish Researchers Cite Rutherrin PDT for Brain Cancer

[Eoganacht]

Photosensitizers for Photodynamic Therapy of Brain Cancers—A Review

by Dorota Bartusik-Aebisher 1, Pawe Wonicki 2, Klaudia Dynarowicz 3, and David Aebisher 4*

 

1 Department of Biochemistry and General Chemistry, Medical College of the University of Rzeszw, 35-959 Rzeszw, Poland

2 Students English Division Science Club, Medical College of the University of Rzeszw, 35-959 Rzeszw, Poland

3 Center for Innovative Research in Medical & Natural Sciences, Medical College of University of Rzeszw, 35-310 Rzeszw, Poland

4 Department of Photomedicine and Physical Chemistry, Medical College of the University of Rzeszw, 35-959 Rzeszw, Poland

* Author to whom correspondence should be addressed

 

Received: 19 July 2023 / Revised: 6 September 2023 / Accepted: 7 September 2023 / Published: 8 September 2023

 

(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Brain Tumors and Nervous System Tumors)

 

Abstract

 

On average, there are about 300,000 new cases of brain cancer each year. Studies have shown that brain and central nervous system tumors are among the top ten causes of death. Due to the extent of this problem and the percentage of patients suffering from brain tumors, innovative therapeutic treatment methods are constantly being sought. One such innovative therapeutic method is photodynamic therapy (PDT). Photodynamic therapy is an alternative and unique technique widely used in dermatology and other fields of medicine for the treatment of oncological and nononcological lesions. Photodynamic therapy consists of the destruction of cancer cells and inducing inflammatory changes by using laser light of a specific wavelength in combination with the application of a photosensitizer. The most commonly used photosensitizers include 5-aminolevulinic acid for the enzymatic generation of protoporphyrin IX, Temoporfin—THPC, Photofrin, Hypericin and Talaporfin. This paper reviews the photosensitizers commonly used in photodynamic therapy for brain tumors. An overview of all three generations of photosensitizers is presented. Along with an indication of the limitations of the treatment of brain tumors, intraoperative photodynamic therapy and its possibilities are described as an alternative therapeutic method.

 

Keywords: brain cancers; photodynamic therapy; molecular targeted therapies; photosensitizers

 

.....................................................................

 

3.2.6. Other Photosensitizers

 

This section describes other photosensitizers used in research on the treatment of brain tumors.

......................................................................
 

The ruthenium-based photosensitizer TLD-1433 with apotransferrin (Rutherrin) was tested in a rat glioblastoma model. In the case of Rutherrin, much lower absorbed energy was sufficient to achieve the LD50 compared to 5-ALA-PDT. This photosensitizer provides a higher rate of specific uptake in tumors compared to the normal brain. After a single treatment, a significant increase in survival was observed in glioblastoma rats with Rutherrin-mediated PDT compared to PpIX. Rutherrin-PDT also showed an increased infiltration of CD8+ T cells into tumors. Rutherrin-PDT was well tolerated, providing safe and effective treatment for RG-2 glioma [93].

 

......................................................................

 

93 
Munegowda, M.A.; Fisher, C.; Molehuis, D.; Foltz, W.; Roufaiel, M.; Bassan, J.; Nitz, M.; Mandel, A.; Lilge, L. 

Efficacy of ruthenium coordination complex-based Rutherrin in a preclinical rat glioblastoma model 

Neurooncol. Adv. 2019, 1, vdz006. [Google Scholar] [CrossRef] [PubMed]

[Oilminerdeluxe]

Now that is a study I want to see start asap. That little thing called money though. Hopefully soon solved.

[StevenBirch]

As I have said it's my opinion that it would be a waste of time raising $462K unless it was only to get them through this next quarter with the expectation that they will be able raise money for GBM or NSCLC from a much more favorable position. If the time frame were longer they would be forced to do a deal with the devil but we know from this last update that they are close to getting BTD

[jmm1228]

Spot on!

[Eoganacht]

Yes it does seem ludicrous. Having an sp of 23 cents CAN at this stage of the game also seems ludicrous. Could big pharma.anti-PDT prejudice really be that strong? At some point some corporate  sharpie is going to realize that a lot of money.could be made here. Or maybe they already realize it? If so, why are they risking a rival getting in first?

[Oilminerdeluxe]

Would be sweet indeed if you are right, Steven.

[StevenBirch]

There is risk but contrary to some I don't think we are close to a buyout just yet so I don't think there is a worry of losing out to a rival. I think they weigh the risk of failure vs BTD approval and having to pay a higher price. Having said that there could be one or more big players buying what they can anonymously but I equate this to the old saying "don't catch a falling

[99942Apophis]

I know of others and to some degree myself that either won't buy or have bought a "toe-in" position that absolutely are waiting for that confirmation of BTD approval to purchase shares. Assuredly share volume will go through the roof on that NR.

[CAinPlap]

Roger has been trying to get the kitty up to $5 million since June. His and Kristina's rolodex has been exhausted as in 2 attempts, only raised a little over $1.5 including their significant participation. As ludicrous as it seems, selling the story has been more difficult than anyone had hoped. Anyone believing Roger was turning away anyone's money is sadly misstaken IMO.

[DJDawg]

Agree that this PP was very underwhelming compared to what they sought. I too feel that they don't have a contact pool big enough or flush enough to raise more this way. Sad as it is such great science. Regardless, the next step is all about the the BDT. Historically 39% of applicants for BTD won it. Plus our science is great so I think we will get there, but don't know if we will get

[Vikingstock]

Where is the 5 million number you quoted  sourced from? Thx

[Kayz88]

https://youtu.be/wNVmMzKDjGQ?t=2011 Up to $5 million dollars. 

[Donein25]

$5 million has been the goal all along. $5m working capital is the threshold for filing a Shelf. I believe that has been the plan, but it has not worked out yet. 

[Vikingstock]

At the AGM, in my opion he said they are not in a position to do the shelf due to minimum requirements  at this time, and started and came back to discuss small pps being the way forward to BTD. The first such pp was announced the next day and now the most recent one. Based on other questions there, control obviously is important as well, impacting available options. Clearly, after BTD it

[DJDawg]

Hand to mouth PP's sort of make sense but clearly there are not enough people on RDW's call list to make it past very small amounts at a time. I truly believe a dumb license agreement covering another part of the world is the way to go. I used to follow SESN and they got a a few million from licensing there unapproved NMIBC drug to Turkey. Doing that doesn't lose you control of your

[BlueFranky]

And might she be doing just that? KAOUTHAR LBIATI, MD, M.SC Director Internationally trained medical doctor, who utilizes her extensive clinical and business background to assist biopharmaceutical organizations to achieve their strategic objectives through: systematic achievement of their value inflection milestones, partnering of their promising

[Benedictus]

I revisited that June PR, linked below,  to re-read her impressive credentials and was reminded of this comment made by the CoB:  "Based on this latest interim clinical data, the Company is commencing to actively explore international partnering, licensing and distribution opportunities for our cancer targeting PDC, Ruvidar™."  So, they began this process just 3 months ago

[wildbird1]

Good point Benedictus...The reason Dr Lbiati is already seeking Big Pharma contracts is because the FDA had no major objections to the pre-BTD submission, the FDA is just asking for a minor update and some clarifications on some data of the pre-BTD submission. (Big Pharma are not dummy, they know that BTD approval is almost a certainty). Yes! Any deal Dr Lbiati will sign on is conditional to the

[FGPstock]

  imo, if BYD was "in the bag" and big pharma knew it, one of the big pharma cos wuld buy a large chunk in order to get to the technology. @ .23 cents and another flopped 460k pp I think that analysis is a stretch. Also, I biieve both the company and everyone on this board never even heard of "pre-btd application" as the company annoiunced the were applying for BTD back

[Oilminerdeluxe]

I think that is the way it is supposed to be. A back and forth, where questions need to be addressed in the application. When those questions are met, the application will be sent in for approval. Or rejection. But let's not hope for that. My blood pressure goes beserk by the mere thought. That small PP spooks me a little, I have to admit. Yes, it might hopefully be because the expect BTD to

[Benedictus]

You are spot on with your comments Dawg. With strong data in hand in a pivotal ph2, a regional licensing deal is exactly what this company should have been pursuing many months ago. Even with this latest disappointing placement the company is still currently on cash fumes, with a quarterly cash burn rate in the $1.1M range. The math just doesn't work if we assume forthcoming BTD by Q1. After

[Lesalpes29]

Yes Dawg it's a deception to see where we stand after all the good results and the science behind. The time to find a partner with money is probably now. Running on fume is not confortable for longs like most here. Maybe ower management now understand they can't continue like this. GL

[jmm1228]

Perhaps RDW has decided to finance had to mouth knowing that soon he can pull off a substantial raise at a decent stock price.

[Legit62]

can you rephrase that statement, makes no sense???

[jmm1228]

"hand to mouth" was intended.

[IvanVanBeethoven]

Here we go again. I think Roger knows enough interested parties. And as shown in my earlier post at the bottom: Investors who are all too keen to participate and even offer themselves, but get no response. The small, cautious PPs seem rather a well-considered choice to me ... !!! Comment by IvanVanBeethovenon Dec 23, 2022 6:58am 325 Views Post# 35188941 RE:RE:RE:RE:Pfizer

[Oilminerdeluxe]

Hope you are right, Beethoven

[CAinPlap]

All I know is that Roger was trying to raise 5 million since June and was only able to get about a third of that. Unless another source of funding is imminent, I suspect we are already running on fumes and will be out of cash in a month or so. 

[Alamir1111]

Jan 9th 4 mil warrants expire at 50c. Btd approval if it works out should give some boost.

[fecats]

CP, I believe you are correct and I think this has been discussed a bit here in the last week or so.It does cause me some concern if they have little ability to raise cash.Maybe BTD will make things different and this has also been discussed.But again I have concerns.Pretty much everyone here assumes it is a given for BTD. That being said.we need an influx of new buyers or the stock is going

[Legit62]

I believe it is a small Canadian company on a small not so good exchange and investors are waiting for the goods before jumping in, i have heard that from several friends who i mentioned this stock to, so until something concrete(BTD,AA) dont think we have many new buyers coming aboard. Everyone here now is someone looking for a big hit before this breaks out, im speaking from the US side. Right

[stocksnbonds458]

Ivan, it would do you friend no good to approach Research Capital. These past 3 PP's have been "non brokered". If  Research Capital were involved it would be a brokered Private Placement. 

[Kayz88]

It sounds like there's 2 camps on this topic. 1) Roger is only raising just enough to get us over the hump until BTD 2) Roger isn't able to raise more than a certain amount because his relationships have been exhausted.  Both are valid possibilities. Both points to BTD whether it's happening or not, one being more positive (Roger willingly raising a smaller amount) and the other

[Legit62]

What was Rogers take in shares last offering? Doubt very much that if this company is less than 3 months from BTD that he doesnt have something lined up. If he doesnt we are all toast

[DJDawg]

I don't think one goes through the trouble of a PP to raise the small amount that he did. I'm with option (2). Perhaps this will be the incentive for RDW to cut a regional licensing deal whereas he may have previously been stuck on controlling everything. I personally think that the only option that is timely is to use the new BOD member from Boston to find some American connections and

[2b7f6fab]

I agree with these sentiments- Perhaps this will be the incentive for RDW to cut a regional licensing deal whereas he may have previously been stuck on controlling everything. I personally think that the only option that is timely is to use the new BOD member from Boston to find some American connections and cash asap  

[2b7f6fab]

Looking at volume over the past month since the pp was initiated there's only about 3 million shares traded on tsxv.  Out of over 200 million shares outstanding comes to only 1.5% turnover.  I only count tsxv volume because looking at the otc pink sheet trades and other minor electronic exchanges and adding them all together to get a total volume amount is probably double counting

[Benedictus]

Right, the glass half full view is that a small pp is just a cash bridge to an imminent regional licensing deal announcement, which shores up all liquidity needs until they achieve BTD approval (likely in Q1 based on the recent MD&A). The half empty view is the Rolodex and investor appetite is currently tapped out regardless of the very strong data, which seems a little implausible.